Report: In big shift, medtech executives grow fonder of U.S. regulatory process

By: Joel Berg

Executives used to lean toward European regulators launching their products in that region. But after a decade of change, they now see the U.S. as a better option. While the FDA gets kudos, the other issue remains challenging: reimbursement.

CONTINUE READING